{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ13596",
      "entity_text" : "nuclear pSer 784 -VCP",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0591" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "Clinically, our data suggest that the level of nuclear pSer 784 -VCP, recognized by the cross reacting pSer 137 -Pfn1 antibody, is associated with poor outcome among patients with breast cancer who received genotoxic therapies (cyclophosphamide, methotrexate, 5FU, and anthracyclines) but not among those receiving the ER-antagonist tamoxifen or no adjuvant systemic therapy at all.",
  "reading_complete" : "2020-08-08T15:30:45Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T15:26:21Z",
  "trigger" : "level",
  "evidence" : [ "level of nuclear pSer 784 -VCP" ],
  "pmc_id" : "7282751",
  "score" : 0
}